Mitochondria and energetic depression in cell pathophysiology

International Journal of Molecular Sciences

Volumn 10, Issue 5, 2009, Pages 2252-2303

  Seppet, Enn ^a   Gruno, Marju ^a   Peetsalu, Ants ^a   Gizatullina, Zemfira ^b   Nguyen, Huu Phuc ^c   Vielhaber, Stefan ^d   Wussling, Manfred H P ^e   Trumbeckaite, Sonata ^f   Arandarcikaite, Odeta ^f   Jerzembeck, Doreen ^b   Sonnabend, Maria ^b   Jegorov, Katharina ^b   Zierz, Stephan ^e   Striggow, Frank ^b   Gellerich, Frank N ^b  

^a UNIVERSITY OF TARTU   (Estonia)

^b KeyNeurotek AG   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d OTTO VON GUERICKE UNIVERSITY   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f KAUNAS UNIVERSITY OF MEDICINE   (Lithuania)

Author keywords

Cancer; Energy depression; Hypoxia; Inflammation; Mitochondria; Mitochondrial cell death; Neurodegenerative diseases

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALCIUM; CYTOCHROME C; GENOMIC DNA;

AEROBIC METABOLISM; APOPTOSIS; CALCIUM CELL LEVEL; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL DEATH; CELL ENERGY; CELL FUNCTION; CYTOPLASM; CYTOSOL; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; ENZYME SYNTHESIS; GLYCOLYSIS; HOMEOSTASIS; HUMAN; HUNTINGTON CHOREA; HYPOXIA; INFLAMMATION; INTOXICATION; ISCHEMIA; MITOCHONDRIAL GENOME; MITOCHONDRION; MUTATION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE PHOSPHORYLATION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PROTEIN SECRETION; REVIEW; STOMACH CANCER;

CANCER; ENERGY DEPRESSION; HYPOXIA; INFLAMMATION; MITOCHONDRIA; MITOCHONDRIAL CELL DEATH; NEURODEGENERATIVE DISEASES;

ADENOSINE TRIPHOSPHATE; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; ENERGY METABOLISM; GLYCOLYSIS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; NEURODEGENERATIVE DISEASES; OXIDATIVE PHOSPHORYLATION;

EID: 67049099126     PISSN: None     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms10052252     Document Type: Review

References (361)

1. Warburg, O.; Geissler, A.W.; Lorenz, S. Genesis of tumor metabolism by vitamin B1 deficiency (thiamine deficiency). Z. Naturforsch. B 1970, 25, 332-333.
2. Luft, R. Luft's disease revisited. Severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control. Mt. Sinai J. Med. 1992, 59, 140-145.
3. Holt, I.J.; Harding, A.E.; Morgan-Hughes J.A. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988, 331, 717-719.
4. Wallace, D.C.; Singh, G.; Lott, M.T.; Hodge, J.A.; Schurr, T.G.; Lezza, A.M.; Elsas, L.J.; Nikoskelainen, E.K. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988, 242, 1427-1430.
5. Triepels, R.H.; Van Den Heuvel, L.P.; Trijbels, J.M.; Smeitink, J.A. Respiratory chain complex I deficiency. Am. J. Med. Gen. 2001, 106, 37-45.
6. Lestienne, P.; Ponsot, G. Kearns-Sayre syndrome with muscle mitochondrial DNA deletion. Lancet. 1988, 8590, 885.
7. Luft, R. The development of mitochondrial medicine. Biochim. Biophys. Acta 1995, 1271, 1-6.
8. Schlame, M.; Ren, M. Barth syndrome, a human disorder of cardiolipin metabolism. FEBS Lett. 2006, 80, 5450-5455.
9. Quinzii, C.M.; Dimauro, S.; Hirano, M. Human coenzyme Q(10) deficiency. Neurochem. Res. 2006, 32, 723-727.
10. Zeviani, M.; Di Donato S. Mitochondrial disorders. Brain 2004, 127, 2153-2172.
11. Smeitink, J.A.; Zeviani, M.; Turnbull, D.M.; Jacobs H.T. Mitochondrial medicine: a metabolic perspective on the pathology of oxidative phosphorylation disorders. Cell. Metab. 2006, 3, 9-13.
12. Morgan-Hughes, J.A.; Hanna, M.G. Mitochondrial encephalomyopathies: the enigma of genotype versus phenotype. Biochim. Biophys. Acta 1999, 1410, 125-145.
13. Wiederkehr, A.; Wollheim, C.B. Minireview: implication of mitochondria in insulin secretion and action. Endocrinology 2006, 147, 2643-2649.
14. Halestrap, A.P. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem. Soc. Trans. 2006, 34, 232-237.
15. Chan, P.H. Mitochondria and neuronal death/survival signaling pathways in cerebral ischemia. Neurochem. Res. 2004, 29, 1943-1949.
16. Galluzzi, L.; Larochette, N.; Zamzami, N.; Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25, 4812-4830.
17. Fantin, V.R.; Leder, P. Mitochondriotoxic compounds for cancer therapy. Oncogene 2006, 25, 4787-4797.
18. Kalman, B.; Leist, T.P. A mitochondrial component of neurodegeneration in multiple sclerosis. Neuromolecular Med. 2003, 3, 147-158.
19. Perl, A.; Gergely, P., Jr.; Banki, K. Mitochondrial dysfunction in T cells of patients with systemic lupus erythematosus. Int. Rev. Immunol. 2004, 23, 293-313.
20. Liu, H.; Pope, R.M. The role of apoptosis in rheumatoid arthritis. Curr. Opin. Pharmacol. 2003, 3, 317-322.
21. Brand, M.D. The efficiency and plasticity of mitochondrial energy transduction. Biochem. Soc. Trans. 2005, 33, 897-904.
22. Gellerich, F.N.; Trumbeckaite, S.; Opalka, J.R.; Chen, Y.; Neuhoff, C.; Schlag, H.; Zierz, S. Mitochondrial dysfunction at sepsis: Evidences from bacteraemic baboons and endotoxaemic rabbits. Bioscience Report 2002, 22, 99-113.
23. Trumbeckaite, S.; Opalka, J.R.; Neuhof, C.; Zierz, S.; Gellerich, F.N. Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function. Eur. J. Biochem. 2000, 268, 1422-1429.
24. Singer, M.; Brealey, D. Mitochondrial dysfunction in sepsis. Biochem. Soc. Symp. 1999, 66, 149-166.
25. Skulachev, V.P. Mitochondria in the programmed death phenomena; a principle of biology: "it is better to die than to be wrong". IUBMB Life 2000, 49, 365-373.
26. Wallace, D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 2005, 39, 359-407.
27. Gellerich, F.N.; Laterveer, F.D.; Zierz, S.; Nicolay, K. The quantitation of ADP diffusion gradients across the outer membrane of heart mitochondria in the presence of macromolecules. Biochim. Biophys. Acta 2002, 1554, 48-56.
28. Parone, P.A.; Martinou, J.C. Mitochondrial fusion and apoptosis: an ongoing trial. Biochim. Biophys. Acta 2006, 1763, 522-530.
29. Sickmann, A.; Reinders, J.; Wagner, Y.; Joppich, C.; Zahedi, R.; Meyer, H.E.; Schonfisch, B.; Perschil, I.; Chacinska, A.; Guiard, B.; Rehling, P.; Pfanner, N.; Meisinger, C. The proteome of Saccharomyces cerevisiae mitochondria. Proc. Natl. Acad. Sci. USA 2003, 100, 13207-13212.
30. Boveris, A.; Alvarez, S.; Navarro, A. The role of mitochondrial nitric oxide synthase in inflammation and septic shock. Free Rad. Biol. Med. 2002, 33, 1186-1193.
31. Ramachandran, A.; Levonen, A.L.; Brookes, P.S.; Ceaser, E.; Shiva, S.; Barone, M.C.; Darley- Usmar, V. Mitochondria, nitric oxide, and cardiovascular dysfunction. Free Rad. Biol. Med. 2002, 33, 1469-1474.
32. Borutaite, V.; Moncada, S.; Brown, G.C. Nitric oxide from inducible nitric oxide synthse sensitizes the inflamed aorta to hypoxic damage via respiratory inhibition. Shock 2005, 23, 319-323.
33. Frost, M.T.; Wang, Q.; Moncada, S.; Singer, M. Hyoxia accelerates nitric oxide-dependent inhibition of mitochondrial complex I in activated macrophages. Am. J. Physiol. 2005, 288, 394-400.
34. Beltran, B.; Orsi, A.; Clementi, E.; Moncada, S. Oxidative stress and S-nitrosylation of proteins in cells. British J. Pharmacol. 2000, 129, 953-960.
35. Borutaite, V.; Budriunaite, A.; Brown, G.C. Reversal nitric oxide-, peroxynitrite- and Snitrosothiol- induced inhibition of mitochondrial respiration or complex I activity by light and thiols. Biochim. Biophys. Acta 2000, 1459, 405-412.
36. Clementi, E.; Brown, G.C.; Feelich, M.; Moncada, S. Persistent inhibition of cellular respiration by nitic oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl. Acad. Sci. USA 1998, 95, 7631-7636.
37. Moncada, S. Nitric oxide and cell respiration: physiology and pathology. Verh. K. Akad. Geneeskd. Belg. 2000, 62, 171-179.
38. Takabayashi, A.; Kawai, Y.; Iwata, S.; Kanai, M.; Denno, R.; Kawada, K.; Obama, K.; Taki, Y. Nitric oxide induces a decrease in the mitochondrial membrane potential of peripheral blood lymphocytes, especially in natural killer cells. Antioxid. Redox. Signal 2000, 2, 673-680.
39. Masci, A.; Mastronicola, D.; Arese, M.; Piane, M.; De Amicis, A.; Blanck, T.; Chessa, L.; Sarti, P. Control of cell respiration by nitric oxide in Ataxia Telangiectasia lymphoblastoid cells. Biochim. Biophys. Acta 2008, 1777, 66-73.
40. Gellerich, F.N.; Gizatullina, Z.; Nguyen, H.P.; Trumbeckaite, S.; Vielhaber, S.; Seppet, E.; Zierz, S.; Landwehrmeyer, B.; Ries, O.; von Hoersten, S.; Striggow, F. Impaired regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic Huntington disease rats. J. Biol. Chem. 2008, 283, 30715-30724.
41. Ichas, F.; Mazat, J.P. From calcium signaling to cell death: two conformations for the mitochondrial permeability transition pore. Switching from low- to high-conductance state. Biochim. Biophys. Acta 1998, 1366, 33-50.
42. Ichas, F.; Jouaville, L.S.; Sidash, S.S.; Mazat, J.P.; Holmuhamedov, E.L. Mitochondrial calcium spiking: a transduction mechanism based on calcium-induced permeability transition involved in cell calcium signalling. FEBS Lett. 1994, 348, 211-215.
43. Bredesen, D.E.; Rammohan V.R.; Mehlen P. Cell death in the nervous system. Nature 2006, 443, 796-802.
44. Vieira, K.L.; Kroemer, G. Pathophysiology of mitochondrial cell death control. Cell. Mol. Life Sci. 1999, 56, 971-976.
45. Gellerich, F.N.; Trumbeckaite, S.; Müller, T.; Chen, Y.; Deschauer, M.; Gizatullina, Z.; Zierz, S. Energetic depression caused by mitochondrial dysfunction. Mol. Cell. Biochem. 2004, 256/257, 391-405.
46. Bernardi, P.; Krauskopf, A.; Basso, E.; Petronelly, V.; Blalchy-Dyson, E.; Di Lisa, F.; Forte, M.A. The mitochondrial permeability transition from in vitro artifact to disase target. FEBS J. 2006, 273, 2077-2099.
47. Kane, G.C.; Behfar, A.; Dyer, R.B.; O'Cochlain, D.F.; Liu, X.K.; Hodgson, D.M.; Reyes, S.; Miki, T.; Seino, S.; Terzic, A. KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension. Hum. Mol. Gen. 2006, 15, 2285-2297.
48. Clarke, S.J.; McStay, G.P.; Halestrap, A.P. Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporine. J. Biol. Chem. 2002, 277, 34793-34799.
49. Irwin, W.A.; Bergamin, N.; Sabatelli, P.; Reggiani, C.; Megighian, A.; Merlini, L.; Braghetta, P.; Columbaro, M.; Volpin, D.; Bressan, G.M.; Bernardi, P.; Bonaldo, P. Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency. Nat. Genet. 2003, 35, 367-371.
50. Green, D.R.; Kroemer, G. The pathophysiology of mitochondrial cell death. Science 2004, 305, 626-629.
51. Seppet, E.K.; Kaambre, T.; Sikk, P.; Tiivel, T.; Vija, H.; Tonkonogi, M.; Sahlin, K.; Kay, L.; Appaix, F.; Braun, U.; Eimre, M.; Saks, V.A. Functional complexes of mitochondria with Ca,MgATPases of myofibrils and sarcoplasmic reticulum in muscle cells. Biochim. Biophys. Acta 2001, 1504, 379-395.
52. Saks, V.A.; Kaambre, T.; Sikk, P.; Eimre, M; Orlova, E.; Paju, K.; Piirsoo, A.; Appaix, F.; Kay, L.; Regitz-Zagrosek, V.; Fleck, E.; Seppet, E. Intracellular energetic units in red muscle cells. Biochem. J. 2001, 326, 643-657.
53. Saks, V.A.; Kuznetsov, A.V.; Vendelin, M.; Guerrero, K.; Kay, L.; Seppet, E.K. Functional coupling as a basic mechanism of feedback regulation of cardiac energy metabolism. Mol. Cell. Biochem. 2004, 256/257, 185-199.
54. Saks, V.; Dzeja, P.; Schlattner, U.; Vendelin, M.; Terzic, A.; Wallimann, T. Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. J. Physiol. 2006, 571, 253-273.
55. Anmann, T.; Eimre, M.; Kuznetsov, A.V.; Andrienko, T.; Kaambre, T.; Sikk, P.; Seppet, E.; Tiivel, T.; Vendelin, M.; Seppet, E.; Saks, V.A. Calcium-induced contraction of sarcomeres changes the regultaion of mitochondrial respiration in permeabilized cardiac cells. FEBS J. 2005, 272, 3145-3161.
56. Neubauer, S.; Horn, M.; Pabst, T.; Godde, M.; Lubke, D.; Jilling, B.; Hahn, D.; Ertl, G. Contributions of 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur. Heart J. 1995, 16, 115-118.
57. Ventura-Claper, R.; Garnier, A.; Veksler, V. Energy metabolism in heart failure. J. Physiol. 2003, 555, 1-13.
58. De Sousa, E.; Veksler, V.; Minajeva, A.; Kaasik, A.; Mateo, P.; Mayoux, E.; Hoerter, J.; Bigard, X.; Serrurier, B.; Ventura-Clapier, R. Subcellular creatine kinase alterations. Implications in heart failure. Circ. Res. 1999, 85, 68-76.
59. Kaasik, A.; Minajeva, A.; De Sousa, E.; Ventura-Clapier, R.; Veksler, V. Nitric oxide inhibits cardiac energy production via inhibition of mitochondrial creatine kinase. FEBS Lett. 1999, 414, 75-77.
60. Nascimben, L.; Ingwall, J.S.; Pauletto, P.; Friedrich, J.; Gwathmey, J.K.; Saks, V.; Pessina, A.C.; Allen, P.D. Creatine kinase system in failing and nonfailing human myocardium. Circulation 1996, 94, 1894-1901.
61. Ponticos, M.; Lu, Q.L.; Morgan, J.E.; Hardie, D.G.; Partridge, T.A.; Carling, D. Dual regulation of the AMP-activated protein kinase provides a novel mechanism for the control of creatine kinase in skeletal muscle. EMBO J. 1998, 17, 1688-1699.
62. Dolder, M.; Walzel, B.; Speer, O.; Schlattner, U.; Wallimann, T. Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation. J. Biol.Chem. 2003, 278, 17760-17766.
63. Zoratti, M.; Szabo, I. The mitochondrial permeability transition. Biochim. Biophys. Acta 1995, 1241, 139-176.
64. Gizatullina, Z.Z.; Chen, Y.; Zierz, S.; Gellerich, F.N. Effects of extramitochondrial ADP on permeability transition of mouse liver mitochondria. Biochim. Biophys. Acta 2005, 1706, 98-104.
65. Gellerich, F.N. The role of adenylate kinase in dynamic compartmentation of adenine nucleotides in the mitochondrial inter membrane space. FEBS Lett. 1992, 297, 55-58.
66. Pucar, D.; Janssen, E.; Dzeja, P.P.; Juranic, N.; Macura, S.; Wieringa, B.; Terzic, A. Compromised energetics in the adenylate kinase AK1 gene knockout heart under metabolic stress. J. Biol. Chem. 2000, 275, 41424-41429.
67. Braun, U.; Paju, K.; Eimre, M.; Seppet, E.; Orlova, E.; Kadaja, L.; Trumbeckaite, S.; Gellerich, F.N.; Zierz, S.; Jockusch, H.; Seppet, E.K. Lack of dystrophin is associated with altered integration of the mitochondria and ATPases in slow-twitch muscle cells of MDX mice. Biochim. Biophys. Acta 2001, 1505, 258-270.
68. Kaasik, A.; Veksler, V.; Boehm, E.; Novotova, M.; Ventura-Clapier, R. From energy store to energy flux: a study in creatine kinase-deficient fast skeletal muscle. FASEB J. 2003, 17, 708-710.
69. Panov, A.V.; Burke, J.R.; Strittmatter, W.J.; Greenamyre, J.T. In vitro effects of polyglutamine tracts on Ca2+-dependent depolarization of rat and human mitochondria: relevance to Huntington's disease. Arch. Biochem. Biophys. 2003, 410, 1-6.
70. Chang, T.W.D.; Rintoul, L.G.; Pandipati, S.; Reynolds, I.J. Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol. Dis. 2006, 22, 388-400.
71. de Cerqueira Cesar, M.; Wilson, J.E. Functional characteristics of hexokinase bound to the type a and type B sites of bovine brain mitochondria. Arch. Biochem. Biophys. 2002, 397, 106-112.
72. Wagner, G.; Kovacs, J.; Löw, P.; Orosz, F.; Ovadi, J. Tubulin and microtubule are potential targets for brain hexokinase binding. FEBS Lett. 2001, 509, 81-84.
73. Schlattner, U.; Forstner, M.; Eder, M.; Stachowiak, O.; Fritz-Wolf, K.; Wallimann, T. Functional aspects of the X-ray structure of mitochondrial creatine kinase: a molecular physiology approach. Mol. Cell. Biochem. 1998, 184, 125-140.
74. Beutner, G.; Rück, A.; Riede, B.; Brdiczka, D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim. Biophys. Acta 1998, 1368, 7-18.
75. Speer, O.; Bäck, N.; Buerklen, T.; Brdicka, D.; Koretsky, A.; Wallimann, T.; Eriksson, O. Octameric mitochondrial creatine kinase induces and stabilizes contact sites between the inner and outer membrane. Biochem. J. 2005, 385, 445-450.
76. da-Silva, W.S.; Gomez-Puyou, A.; de Gomez-Puyou, M.T.; Moreno-Sanchez, R.; De Felice, F.G.; de Meis, L.; Oliveira, M.F.; Galina, A. Mitochondrial bound hexokinase activity as a preventive antioxidant defense: steady-state ADP formation as a regulatory mechanism of membrane potential and reactive oxygen species generation in mitochondria. J. Biol. Chem. 2004, 279, 39846-39855.
77. Meyer, L.E.; Machado, L.B.; Santiago, A.P.; da-Silva, W.S.; De Felice, F.G.; Holub, O.; Oliveira, M.F.; Galina, A. Mitochondrial creatine kinase activity prevents reactive oxygen species generation: Antioxidant role of mitochondrial kinase-dependent ADP re-cycling activity. J. Biol. Chem. 2006, 281, 37361-37371.
78. David, S.; Shoemaker, M.; Haley, B.E. Abnormal properties of creatine kinase in Alzheimer's disease brain: correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Brain Res. Mol. Brain Res. 1998, 54, 276-287.
79. Wendt, S.; Dedeoglu, A.; Speer, O.; Wallimann, T.; Beal, M.F.; Andreassen, O. Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free Rad. Biol. Med. 2002, 32, 920-926.
80. Halliwell, B. Oxidative stress and neurodegeneration: where are we now? J. Neurochem. 2006, 97, 1634-1658.
81. Kwong, J.Q.; Beal, M.F.; Manfredi, G. The role of mitochondria in inherited neurodegenerative diseases. J. Neurochem. 2006, 97, 1659-1675.
82. Callahan L.A; Supinski, G.S. Diaphragm and cardiac mitochondrial creatine kinases are impaired in sepsis. J. Appl. Physiol. 2007, 102, 44-53.
83. Denton, R.M.; McCormack, J.G. On the role of the calcium transport cycle in heart and other mammalian mitochondria. FEBS Lett. 1980, 119, 1-8.
84. McCormack, J.G.; Denton R.M. The role of intramitochondrial Ca2+ in the regulation of oxidative phosphorylation in mammalian tissues. TIBS 1986, 11, 258-262.
85. Carafoli, E. Mitochondrial pathology: An overview. Ann. NY Acad. Sci. 1986, 488, 1-18.
86. Wussling, M.H.P.; Krannich, K.; Landgraf, G.; Herrmann-Frank, A.; Wiedenmann, D.; Gellerich, F.N.; Podhaisky, H. Sarcoplasmatic reticulum vesicles embedded in agarose gel exhibit propagating calcium waves. FEBS Lett. 1999, 463, 103-109.
87. Gunter, T.E.; Pfeiffer, D.R. Mechanisms by which mitochondria transport calcium. Am. J. Physiol. 1990, 258, C755-786.
88. Montero, M.; Alonso, M.T.; Carnicero, E.; Cuchill-Ibanez, I.; Albillos, A.; Garcia, A.G.; Garcua- Sancho, J.; Alvarez, J. Chomaffin-cell stimulation triggers fast millimolar mitochondrial Ca2+ transients that modulate secretion. Nat Cell. Biol. 2000, 2, 57-61.
89. Nicchitta, C.V.; Williamson, J.R. Spermine. A regulator of mitochondrial calcium cycling. J. Biol. Chem. 1984, 259, 12978-12983.
90. McCormack, J.G. Effects of spermine on mitochondrial Ca2+ transport and the ranges of extramitochondrial Ca2+ to which the matrix Ca2+-sensitive dehydrogenases respond. Biochem. J. 1989, 264, 167-174.
91. Chalmers, S.; Nicholls, D.G. The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. J. Biol. Chem. 2003, 278, 19062-19070.
92. Bernardi, P. Mitochondrial transport of cations: channels, exchangers, and permeability transition. Phys. Rev. 1999, 79, 1127-1155.
93. Korzeniewski, B. Regulation of oxidative phosphorylation through parallel activation. Biophys. Chem. 2007, 129, 93-110.
94. Pardo, B.; Contreras, L.; Serrano, A.; Ramos, M.; Kobayashi, K.; Iijima, M.; Saheki, T.; Satrustegui, J. Essential role of aralar in the transduction of small Ca2+ signals to neuronal mitochondria. J. Biol. Chem. 2006, 281, 1039-1047.
95. Palmieri, L.; Pardo, B.; Lasorsa, F.M.; del Arco, A.; Kobayashi, K.; Iijima, M.; Runswick, M.J.; Walker, J.E.; Saheki, T.; Satrustegui, J.; Palmieri, F. Citrin and aralar1 are Ca(2+)-stimulated aspartate/glutamate transporters in mitochondria. EMBO J. 2001, 20, 5060-5069.
96. Molinari, F.; Raas-Rothschild, A.; Rio, M.; Fiermonte, G.; Encha-Razavi, F.; Palmieri, L.; Palmieri, F.; Ben-Neriah, Z.; Kadhom, N.; Vekemans, M.; Attie-Bitach, T.; Munnich, A.; Rustin, P.; Colleaux, L. Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am. J. Hum. Genet. 2005, 76, 334-339.
97. Hoek, J.B.; Njogu, R.M. The role of glutamate transport in the regulation of the pathway of proline oxidation in rat liver mitochondria. J. Biol.Chem. 1980, 255, 8711-8718.
98. Gincel, D.; Zaid, H., Shoshan-Barmatz, V. Calcium binding and translocation by the voltagedependent anion channel: a possible regulatory mechanism in mitochondrial function. Biochem. J. 2001, 358, 147-155.
99. Bernardi, P.; Veronese, P.; Petronilli, V. Modulation of the mitochondrial cyclosporin Asensitive permeability transition pore. I. Evidence for two separate Me2+ binding sites with opposing effects on the pore open probability. J. Biol.Chem. 1993, 268, 1005-1010.
100. Wellington, C.L.; Ellerby, L.M.; Gutekunst, C.A.; Rogers, D.; Warby, S.; Graham, R.K.; Loubser, O.; van Raamsdonk, J.; Singaraja, R.; Yang, Y.Z.; Gafni, J.; Bredesen, D.; Hersch, S.M.; Leavitt, B.R.; Roy, S.; Nicholson, D.W.; Hayden, M.R. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J. Neurosci. 2002, 22, 7862-7872.
101. Hackam, A.S; Singaraja, R.; Wellington, C.L.; Metzler, M.; McCutcheon, K.; Zhang, T.; Kalchman, M.; Hayden, M.R; The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell. Biol. 1998, 141, 1097-105.
102. Nosek, M.T., Dransfield, D.T.; Aprille, J.R. Calcium stimulates ATP-Mg/Pi carrier activity in rat liver mitochondria. J. Biol. Chem. 1990, 265, 8444-8450.
103. Fiermonte, G.; De Leonardis, F.; Todisco, S., Palmieri, L.; Lasorsa, F.M.; Palmieri, F. Identification of the mitochondrial ATP-Mg/Pi transporter. Bacterial expression, reconstitution, functional characterization, and tissue distribution. J. Biol. Chem. 2004, 279, 30722-30730.
104. Hagen, T.; Lagace, C.J.; Modica-Napolitano, J.S.; Aprille, J.R. Permeability transition in rat liver mitochondria is modulated by the ATP-Mg/Pi carrier. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 285, G274-G281.
105. del Arco, A.; Satrustegui, J. Identification of a novel human subfamily of mitochondrial carriers with calcium-binding domains. J. Biol. Chem. 2004, 279, 24701-24713.
106. Litsky, M.L.; Pfeiffer, D.R. Regulation of the mitochondrial Ca2+ uniporter by external adenine nucleotides: the uniporter behaves like a gated channel which is regulated by nucleotides and divalent cations. Biochemistry 1997, 36, 7071-7080.
107. Igbavboa, U.; Pfeiffer, D.R. EGTA inhibits reverse uniport-dependent Ca2+ release from uncoupled mitochondria. Possible regulation of the Ca2+ uniporter by a Ca2+ binding site on the cytoplasmic side of the inner membrane. J. Biol. Chem. 1988, 263, 1405-1412.
108. Bathori, G.; Csordas, G.; Garcia-Perez, C.; Davies, E.; Hajnoczky, G. Ca2+-dependent control of the permeability properties of the mitochondrial outer membrane and voltage-dependent anionselective channel (VDAC). J. Biol. Chem. 2006, 281, 17347-17358.
109. Rizzuto, R.; Pozzan, T. Microdomains of intracellular Ca2+: molecular determinats and functional consequences. Physiol. Rev. 2006, 86, 369-408.
110. Rizzuto, R.; Simpson, A.W.; Brini, M.; Pozzan, T. Rapid changes of mitochondrial Ca2+ revealed by specifically targeted recombinant aequorin. Nature 1992, 358, 325-327.
111. Rizzuto, R.; Brini, M.; Murgia, M.; Pozzan T. Microdomains with high Ca2+ close to IP3- sensitive channels that are sensed by neighboring mitochondria. Science 1993, 262, 744-747.
112. Ichas, F.; Jouaville, L.S.; Mazat, J.P. Mitochondria are excitable organelles capable of generating and conveying electrical and calcium signals. Cell 1997, 89, 1145-1153.
113. Landgraf, G.; Gellerich, F.N.; Wussling, M.H.P. Inhibitors of SERCA and mitochondrial Cauniporter decrease velocity of calcium waves in rat cardiomyocytes. Mol. Cell. Biochem. 2004, 256/257, 379-386.
114. Wasniewska, M.; Karczmarewicz, E.; Pronicki, M.; Piekutowska Abramczak, K.; Zablocki, K.; Popowska, E.; Pronicka, E.; Duszynski, J. Abnormal calcium homeostasis in fibroblasts from patients with Leigh disease. Biophys. Biochem. Res. Comm. 2001, 283, 687-693.
115. Rubinsztein, D.C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 2006, 443, 780-786.
116. Lansbury, P.T.; Lashuel, H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006, 443, 774-779.
117. Harjes, P.; Wanker, E.E. The hunt for huntingtin function: interaction partners tell many different stories. Trends. Biochem. Sci. 2003, 28, 425-433.
118. Lin, M.T.; Beal, M.F. Mitochondrial dysfunction and oxidative stress in neurodegeneration. Nature 2006, 443, 787-795.
119. Ambrose, C.M.; Duyao, M.P.; Barnes, G.; Bates, G.P.; Lin, C.S.; Srinidhi, J.; Baxendale, S.; Hummerich, H.; Lehrach, H.; Altherr, M. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat. Cell. Mol. Genet. 1994, 20, 27-38.
120. Li, S.H.; Schilling, G.; Young, W.S. 3rd; Li, X.J.; Margolis, R.L.; Stine, O.C.; Wagster, M.V.; Abbott, M.H.; Franz, M.L.; Ranen, N.G., et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron 1993, 11, 985-993.
121. Langbehn, D.R.; Brinkman, R.R.; Falush, D.; Paulsen, J.S.; Hayden, M.R.; International Huntington's Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin. Gen. 2004, 65, 276-277.
122. Vonsattel, J.P.; DiFiglia, M.J. Huntington disease. J. Neuropathol. Exp. Neurol. 1998, 57, 369-384.
123. Browne, S.E.; Beal, M.F. The energetics of Huntington's disease. Neurochem. Res. 2004, 29, 531-546.
124. Djousse, L.; Knowlton, Cupples, L.A.; Marder, K.; Shoulson, I.; Myers, R.H. Weight loss in early stage of Huntington's disease. Neurologie 2002, 69, 1325-1330.
125. Sanberg, P.R.; Fibiger, H.C.; Mark, R.C. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med. J. Aust. 1981, 1, 407-409.
126. Koroshetz, W.J.; Jenkins, B.G.; Rosen, B.R.; Beal, M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 1997, 41, 160-165.
127. Grunewald, T.; Beal, M.F. Bioenergetics in Huntington's disease. Ann. NY Acad. Sci. 1999, 893, 203-213.
128. Browne, S.E.; Bowling, A.C.; MacGarvey, U.; Baik, M.J.; Berger, S.C.; Muqit, M.M.; Bird, E.D.; Beal, M.F. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 1997, 41, 646-653.
129. Tabrizi, S.J.; Cleeter, M.W.; Xuereb, J.; Taanman, J.W.; Cooper, J.M.; Schapira, A.H. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann. Neurol. 1999, 45, 25-32.
130. Goebel, H.H.; Heipertz, R.; Scholz, W.; Iqbal, K.; Tellez-Nagel, I. Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology 1978, 28, 23-31.
131. Tellez-Nagel, I.; Johnson, A.B.; Terry, R.D. Studies on brain biopsies with Huntington's chorea. J. Neuropathol. Exp. Neurol. 1974, 33, 308-332.
132. Underwood, B.R.; David Broadhurst, D.; Dunn, W.B.; Ellis, D.I.; Michell, A.W.; Vacher, C.; Mosedale, D.E.; Kell, D.B.; Barker, R.A.; Grainger, D.J.; Rubinsztein, D.C. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles Brain, 2006, 129, 877-886.
133. Panov, A.V.; Gutekunst, C.A.; Leavitt, B.R.; Hayden, M.R.; Burke, J.R.; Strittmatter, W.J.; Greenamyre, J.T. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci. 2002, 5, 731-736.
134. Choo, Y.S.; Johnson, G.V.; MacDonald, M.; Detloff, P.J.; Lesort, M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet. 2004, 13, 1407-1420.
135. Milakovic, T.; Quintanilla, R.A.; Johnson, G.V. Mutant huntingtin expression induces mitochondrial calcium handling defects in clonal striatal cells: functional consequences. J. Biol. Chem. 2006, 281, 34785-34795.
136. Rockabrand, E.; Slepko, N.; Pantalone, A.; Nukala, V.N.; Kazantsev, A.; Marsh, J.L.; Sullivan, P.G.; Steffan, J.S.; Sensi, S.L.; Thompson, L.M. The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 2007, 16, 61-77.
137. Brustovetsky, N.; LaFrance, R.; Purl, K.J.; Brustovetsky, T.; Keene, C.D.; Low, W.C.; Dubinsky, J.M. Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease. J. Neurochem. 2005, 93, 1361-1370
138. Oliveira, J.M.; Jekabsons, M.B.; Chen, S.; Lin, A.; Rego, A.C.; Goncalves, J.; Ellerby, L.M.; Nicholls, D.G. Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J. Neurochem. 2007, 101, 241-249.
139. Gizatullina, Z.Z.; Chen, Y.; Lindenberg, K.S.; Harjes, P.; Striggow, F.; Zierz, S.; Gellerich, F.N. Increased calcium sensitivity of respiration and of permeability transition in mitochondria of skeletal muscle in transgenic the R6/2mice with mouse model for Huntington disease. Ann. Neurol. 2006, 59, 407-411.
140. Kuznetsov, A.V.; Veksler, V.; Gellerich, F.N.; Saks, V.; Margreiter, R.; Kunz, W.S. Analysis of mitochondrial function in situ, in permeabilized muscles fibers, tissues and cells. Nature Protoc. 2008, 3, 965-976.
141. Kosinski, C.M.; Schlangen, C.; Gellerich, F.N.; Gizatullina, Z.; Deschauer, M.; Schiefer, J.; Young, A.B.; Landwehrmeyer, G.B.; Toyka, K.V.; Sellhaus, B.; Lindenberg, K.S. Myopathy as a first symptom of Huntington's disease in a marathon runner. Mov. Disord. 2007, 22, 637-640.
142. Bezprozvanny, I.; Hayden, M.R. Deranged neuronal calcium signaling and Huntington disease Biochem. Biophys. Res. Commun. 2004, 322, 1310-1317
143. Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C.; Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S.W.; Bates, G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87, 493-506.
144. von Hörsten, S.; Schmitt, I.; Nguyen, H.P.; Holzmann, C.; Schmidt, T.; Walther, T.; Bader, M.; Pabst, R.; Kobbe, P.; Krotova, J.; Stiller, D.; Kask, A.; Vaarmann, A; Rathke-Hartlieb, S.; Schulz, J.B.; Grasshoff, U.; Bauer, I.; Vieira-Saecker, A.M.; Paul, M.; Jones, L.; Lindenberg, K.S.; Landwehrmeyer, B.; Bauer, A.; Li, X.J.; Riess, O. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 2003, 12, 617-624.
145. Petrasch-Parwez, E.; Nguyen, H.P.; Lobbecke-Schumacher, M.; Habbes, H.W.; Wieczorek, S.; Riess, O.; Andres, K.H.; Dermietzel, R.; Horsten, S. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. J. Comp. Neurol. 2007, 501, 716-730.
146. Grimm, S.; Brdiczka, D. The permeability transition pore in cell death. Apoptosis 2007, 12, 841-855.
147. Wicker, U.; Bücheler, K.; Gellerich, F.N.; Wagner, M.; Kapischke, M.; Brdiczka, D. Effect of macromolecules on the structure of the mitochondrial inter-membrane space and the regulation of hexokinase. Biochim. Biophys. Acta 1993, 1142, 228-239.
148. Schapira, A.H.; Cooper. J.M.; Dexter, D.; Jenner, P.; Clark, J.B.; Marsden, C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1, 1269.
149. Schapira, A.H.; Mann, V.M.; Cooper J.M.; Dexter, D.; Daniel, S.E.; Jenner, P.; Clark, J.B.; Marsden, C.D. Anatomic and diseases specificity of NADH CoQ1 reductase (complex I deficiency) in Parkinson's disease. J. Neurochem. 1990, 55, 2142-2145.
150. Krige, D.; Caroll, M.T.; Cooper, J.M.; Marsden, C.D.; Schapira A.H. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann. Neurol. 1992, 32, 782-788.
151. Parker, W.D., Jr.; Boyson, S.J.; Parks, J.K. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 1989, 26, 719-723.
152. Winkler Stuck, K.; Kirches, E.; Mawrin, C.; Dietzmann, K.; Lins, H.; Wallesch, C.W.; Kunz, W.S.; Wiedemann F.R. Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson's disease. J. Neural. Transm. 2005, 112, 499-518.
153. Tetrud, J.W.; Langston, J.W. The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. Science 1989, 245, 519-522.
154. Betarbet, R.; Sherer, T.B.; MacKenzie, G.; Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 2000, 3, 1301-1306.
155. McCormack, A.L.; Thiruchelvam, M.; Manning-Bog. A.B.; Thiffault, C.; Langston, J.W.; Cory- Slechta. D.A.; Di Monte, D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol. Dis. 2002, 10, 119-127.
156. Dawson, T.M.; Dawson, V.L. Neuroprotective and neurorestorative strategies for Parkinson's disease. Nat. Neurosci. 2002, 5, 1058-1061.
157. Soto-Otero, R.; Sanmartin-Suarez, C.; Sanchez-Iglesias, S.; Hermida-Ameijeiras, A.; Sanchez- Sellero, I.; Mendez-Alvarez, E. Study on the ability of 1,2,3,4-tetrahydropapaveroline to cause oxidative stress: Mechanisms and potential implications in relation to parkinson's disease. J. Biochem. Mol. Toxicol. 2006, 20, 209-220.
158. Simon, D.K.; Pulst, S.M.; Sutton, J.P.; Browne, S.E.; Beal, M.F.; Johns, D.R. Familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation. Neurology 1999, 53, 1787-1793.
159. Luoma, P.; Melberg, A.; Rinne, J.O.; Kaukonen, J.A.; Nupponen, N.N.; Chalmers, R.M.; Oldfors, A.; Rautakorpi, I.; Peltonen, L.; Majamaa, K.; Somer, H.; Suomalainen, A. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004, 364, 875-882.
160. Song, D.D.; Shults, C.W.; Sisk, A.; Rockenstein, E.; Masliah, E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 2004, 186,158-172.
161. Martin, L.J.; Pan, Y.; Price, A.C.; Sterling, W.; Copeland, N.G.; Jenkins, N.A.; Price, D.L., Lee, M.K. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. J. Neurosci. 2006, 26, 41-50.
162. Klivenyi, P.; Siwek, D.; Gardian, G.; Yang, L.; Starkov, A.; Cleren, C.; Ferrante, R.J.; Kowall, N.W.; Abeliovich, A.; Beal, M.F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol. Dis. 2006, 21, 541-548.
163. Pesah, Y.; Pham, T.; Burgess, H.; Middlebrooks, B.; Verstreken, P.; Zhou, Y.; Harding, M.; Bellen, H.; Mardon, G. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004, 131, 2183-2194.
164. Palacino, J.J.; Sagi, D.; Goldberg, M.S.; Krauss, S.; Motz, C.; Wacker, M.; Klose, J.; Shen, J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 2004, 279, 18614-18622.
165. Muftuoglu, M.; Elibol, B.; Dalmizrak, O.; Ercan, A.; Kulaksiz, G.; Ogus, H.; Dalkara, T.; Ozer, N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov. Disord. 2004, 19, 544-548.
166. Darios, F.; Corti, O.; Lucking, C.B.; Hampe, C.; Muriel, M.P.; Abbas, N.; Gu, W.J.; Hirsch, E.C.; Rooney, T.; Ruberg, M.; Brice, A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum. Mol. Genet. 2003, 12, 517-526.
167. Canet-Aviles, R.M.; Wilson, M.A.; Miller, D.W.; Ahmad, R.; McLendon, C.; Bandyopadhyay, S.; Baptista, M.J.; Ringe, D.; Petsko, G.A.; Cookson, M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. USA 2004, 101, 9103-9108.
168. Kim, R.H.; Smith, P.D.; Aleyasin, H.; Hayley, S.; Mount, M.P.; Pownall, S.; Wakeham, A.; You- Ten, A.J.; Kalia, S.K.; Horne, P.; Westaway, D.; Lozano, A.M.; Anisman, H.; Park, D.S.; Mak, T.W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. USA 2005, 102, 5215-5220.
169. Petit, A.; Kawarai, T.; Paitel, E.; Sanjo, N.; Maj, M.; Scheid, M.; Chen, F.; Gu, Y; Hasegawa, H.; Salehi-Rad, S.; Wang, L.; Rogaeva, E.; Fraser, P.; Robinson, B.; St George-Hyslop, P.; Tandon, A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J. Biol. Chem. 2005, 280, 34025-34032.
170. Deng, H.; Jankovic, J.; Guo, Y.; Xie, W.; Le, W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem. Biophys. Res. Commun. 2005, 337, 1133-1138.
171. Hald, A.; Lotharius, J. Oxidative stress and inflammation in Parkinson's disease: Is there a causal link? Exp. Neuro. 2005, 193, 179-290.
172. Haddad, J.J.; Harb, H.L. Cytokines and the regulation of hypoxia-inducible factor (HIF)-1α. Int. Immunopharm. 2005, 5, 461-483.
173. Haddad, J.J.; Land S.C. A non-hypoxic, ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α. FEBS Lett. 2001, 505, 269-274.
174. Bai, Y.; Onuma, H.; Bai, X.; Medvedev, A.V.; Misukonis, M.; Weinberg, J.B.; Cao, W.; Robidoux, J.; Floering, L.M.; Daniel, K.W.; Collins, S. Persistent nuclear factor- κB activation in Ucp2-/- mice leads to enhanced nitric oxide and inflammatory cytokine production. J. Biol. Chem. 2005, 280, 19062-19069.
175. Emre, Y.; Hurtaud, C.; Nübel, T.; Criscuolo, F.; Ricquier, D.; Cassard-Doulcier, A.M. Mitochondria contribute to LPS-induced MAPK activation via uncoupling protein UCP2 in macrophages. Biochem. J. 2007, 402, 271-278.
176. Schulze-Osthoff, K.; Bakker, A.C., Vanhasebroeck, B.; Beyaert, R.; Jacob, W.A.; Fiers, W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. J. Biol. Chem. 1992, 267, 5317-5323.
177. Goossens, V.; Stange, G.; Moens, K.; Pipeleers, D.; Grooten, J. Regulation of tumor necrosis factor-induced, mitochondria- and reactive oxygen species-dependent cell death by the electron flux through the electron transport chain complex I. Antioxid. Redox Signal. 1999, 1, 285-295.
178. Itoh, S.; Lemay, S.; Osawa, M.; Che, W.; Duan, Y.; Tompkins, A.; Brookes, P.S.; Sheu, S.S.; Abe, J.I. Mitochondrial Dok-4 recruits Src kinase and regulates NF-kB activation in endothelial cells. J. Biol. Chem. 2005, 280, 26383-26396.
179. Le Moine, O.; Louis, H.; Stordeur, P.; Collet, J.M.; Goldman, M.; Deviere, J. Role of reactive oxygen intermediates in interleukin 10 release after cold liver ischemia and reperfusion in mice. Gastroenterology 1997, 113, 1701-1706
180. Llorente, L.; Zou, W.; Levy, Y.; Richaud-Patin, Y.; Wijdenes, J.; Alcocer-Varele, J.; Morel- Fourrier, B.; Brouet, J.C.; Alarcon-Segovia, D.; Galanaud, P.; Emilie, D. Role of interleukin 10 in the B lymphocyte hyperactivity and antibody production of human systemic lupus erythematosus. J. Exp. Med. 1995, 181, 839-844.
181. Marumo, T.; Schini-Kerth, V.B.; Fisslthaler, B.; Busse, R. Platelet-derived growth factorstimulated superoxide anion production modulates activation of transcription factor NF-kappaB and expression of monocyte chemoattractant protein 1 in human aortic smooth muscle cells. Circulation 1997, 96, 2361-2367.
182. Mogensen, T.H.; Melchjorsen, J.; Höllsberg, P.; Paludan, S.R. Activation of NF-κB invirusinfected macrophages is dependent on mitochondrial oxidative stress and intracellular calcium: Downstream involvement of the kinases TGF-β-activated kinase 1, mitogen activated kinase/extracellular signal-regulated kinase kinase 1, and IκB kinase. J. Immunol. 2003, 170, 6224-6233.
183. Haynes, V.; Elfering, S.; Traaseth, N.; Giulivi, C. Mitochondrial nitric-oxide synthase: enzyme expression, characterization, and regulation. J. Bioenerg. Biomembr. 2004, 36, 341-346.
184. Trumbeckaite, S.; Opalka, J.R.; Neuhof, C.; Zierz, S.; Gellerich, F.N. Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function. Eur. J. Biochem. 2000, 268, 1422-1429.
185. Gellerich, F.N.; Trumbeckaite, S.; Hertel, K.; Zierz, S.; Müller-Werdan, U.; Werdan K.; Redl, H.; Schlag G. Impaired energy metabolism in hearts of septic baboons: diminished activities of complex I and complex II of the mitochondrial respiratory chain. Shock 1999, 11, 336-341.
186. Bojunga, J.; Dresar-Mayert, B.; Usadel, K.H.; Kusterer, K.; Zeuzem, S. Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats. Biochem. Biophys. Res. Commun. 2004, 316, 771-780;
187. Munoz-Fernandez, M.A.; Fresno, M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog. Neurobiol. 1998, 56, 307-340.
188. Anderson, H.D.; Rahmutula, D.; Gardner, D.G. Tumor necrosis factor-a inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells. J. Biol.Chem. 2004, 279, 963-969.
189. Tatsumi, T.; Matoba, S.; Kawahara, A.; Keira, N.; Shiraishi, J.; Akashi, K.; Kobara, M.; Tanaka, T.; Katamura, M.; Nakagawa, C.; Ohta, B.; Shirayama, T.; Takeda, K.; Asayama, J.; Fliss, H.; Nakagawa, M., et al. Cytokine-induced nitric oxide production inhibits mitochondrial energy production and impairs contractile function in rat cardiac myocytes. J. Am. Coll. Cardiol. 2000, 35, 1338-1346.
190. Valerio, A.; Cardile, A.; Cozzi, V.; Bracale, R.; Tedesco, L.; Pisconti, A.; Palomba, L.; Cantoni, O.; Clement, E.; Moncada, S.; Carruba, M.O.; Nisoli, E. TNF-α downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J. Clin. Invest. 2006, 116, 2791-2798.
191. Galmiche, A.; Rassow, J.; Doye, A.; Cagnol, S.; Chambard, J.C.; Contamin, S.; de Thillot, V.; Just, I.; Ricci, V.; Solcia, E.; Van Obberghen, E.; Boquet, P. The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release. EMBO J. 2000, 19, 6361-6370.
192. Ashktorab, H.; Frank, S.; Khaled, A.R.; Durum, S.K.; Kifle, B.; Smoot D.T. Bax translocation and mitochondrial fragmentation induced by Helicobacter pylori. Gut 2004, 53, 805-813.
193. Kimura, M.; Goto, S.; Wada, A.; Yahiro, K.; Niidome, T.; Hatakeyama, T.; Aoyagi, H.; Hirayama, T.; Kondo, T. Vacuolating cytotoxin purified from Helicobacter pylori causes mitochondrial damage in human gastric cells. Microb. Pathog. 1999, 26, 45-52.
194. Xia, H.H.; Talley, N.J. Apoptosis in gastric epithelium induced by Helicobacter pylori infection: Implications in gastric carcinogenesis. Am. J. Gastroenterol. 2001, 96, 16-26.
195. Jung, H.K.; Lee, K.E.; Chu, S.H.; Yi, S.I. Reactive oxygen species activity, mucosal lipoperoxidation and glutathione in Helicobacter pylori-infected gastric mucosa. J. Gastroenterol. Hepatol. 2001, 16, 1336-1340.
196. Kubota, Y.; Kato, K.; Dairaku, N.; Koike, T.; Iijima, K.; Imatani, A.; Sekine, H.; Ohara, S.; Matsui, H.; Shimosegawa, T. Contribution of glutamine synthetase to ammonia-induced apoptosis in gastric mucosal cells. Digestion 2004, 69, 140-148.
197. Aulak, K.S.; Koeck, T.; Crabb, J.W.; Stuehr, D.J. Dynamics of protein nitration in cells and mitochondria. Am. J. Physiol. 2004, 286, H30-H38.
198. Lee, J.H.; Yang, E.S; Park, J.W. Inactivation of NADP+-dependent isocitrate dehydrogenase by peroxynitrite. J. Biol. Chem. 2003, 278, 52360-52371.
199. Cramer, T.; Yamanishi, Y.; Clausen, B.E.; Förster, I.; Pawlinski, R.; Mackman, N.; Haase, V.H.; Jaenisch, R.; Corr, M.; Nizet, V.; Firestein, G.S.; Gerber, H.P.; Ferrara, N.; Johnson, R.S. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 2003, 112, 645-657.
200. Dewson, G.; Cohen, G.M.; Wardlaw, A.J. Interleukin-5 inhibits translocation of Bax to the mitochondria, cytochrome c release, and activation of caspoases in human eosinofils. Blood 2001, 98, 2239-2247.
201. Maianski, N.A.; Mul, F.P.J.; van Buul, J.D.; Roos, D.; Kuijpers, T.W. Granulocyte colonystimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood 2002, 99, 672-679.
202. Gergely, P., Jr; Niland, B.; Gonchoroff, N.; Pullmann, R., Jr.; Phillips, P.E.; Perl, A. Persistent mitochondrial hyperpolarization, increased reactive oxygen intermediate production, and cytoplasmic alkalization characterize altered IL-10 signalling in patients with systemic lupus erythematosus. J. Immunol. 2002, 169, 1092-1101.
203. Perl, A.; Gergely, P., Jr; Nagy, G.; Koncz, A.; Banki, K. Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol. 2004, 25, 360-367.
204. Fossati, G.; Moulding, D.A.; Spiller, D.G.; Moots, R.J.; White, M.R.H.; Edwads, S.W. The mitochondrial network of human neutrophils: Role in chemotaxis, phagocytosis, respiratory burst activation, and commitment of apoptosis. J. Immunol. 2003, 170, 1964-1972.
205. Peachman, K.K.; Lyles, D.S.; Bass, D.A. Mitochondria in eosinophils: Functional role in apoptosis but not respiration. Proc. Natl. Acad. Sci. USA 2001, 98, 1717-1722.
206. Vats, D.; Mukundan, L.; Odegaard, J.I.; Zhang, L; Smith, K.L.; Morel, C.R.; Greaves, D.R.; Murray, P.J.; Chawla, A. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation. Cell Metab. 2006, 4, 13-24.
207. Lacy-Hulbert, A.; Moore, K.J. Designer macrophages: oxidative metabolism fuels inflammation repair. Cell Metab. 2006, 4, 7-8.
208. Haden, D.; Suliman, H.B.; Carraway, M.S.; Welti-Wolf, K.E.; Ali, A.S.; Shitara, H.; Yonekawa, H.; Piantadosil, C.A. Mitochondrial biogenesis restores oxidative metabolism during Staphylococcus aureus sepsis. Am. J. Resp. Crit. Car. Med. 2007, 176, 768-777.
209. Baines, C.P.; Song, C.X.; Zheng, Y.T.; Wang, G.W.; Zhang, J.; Wang, O.L.; Guo, Y.; Bolli, R.; Cardwell, E.M.; Ping, P. Protein kinase cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ. Res. 2003, 92, 873-880.
210. Baines, C.P.; Zhang, J.; Wang, G.W.; Zheng, Y.T.; Xiu, J.X.; Cardwell, E.M.; Bolli, R.; Ping, P. Mitochondrial PKCe and MAPK form signaling modules in the murine heart: enhanced mitochondrial PKCe-MAPK interactions and differential MAPK activation in PKCe-induced cardioprotection. Circ. Res. 2002, 90, 390-397.
211. Chen, Q.; Lin, R.Y.; Rubin, C.S. Organelle-specific targeting of protein kinase AII (PKAII): molecular and in situ characterization of murine A kinase anchor proteins that recruit regulatory subunits of PKAII to the cytoplasmic surface of mitochondria. J. Biol. Chem. 1997, 272, 15247-15257.
212. Technikova-Dobrova, Z.; Sardanelli, A.M.; Speranza, F.; Scacco, S.; Signorile, A.; Lorusso, V.; Papa, S. Cyclic adenosine monophosphate-dependent phosphorylation of mammalian mitochondrial proteins: enzyme and substrate characterization and functional role. Biochemistry 2001, 4, 13941-13947.
213. Harada, H.; Becknell, B.; Wilm, M.; Mann, M.; Huang, L.J.; Taylor, S.S.; Scott, J.D.; Korsmeyer, S. J. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol. Cell 1999, 3, 413-422.
214. Hoppeler, H.; Vogt, M.; Weibel, E.R.; Fluck, M. Response of skeletal muscle to hypoxia. Exp. Physiol. 2003, 88, 109-119.
215. Höckel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biological, and molecular aspects. J. Natl. Cancer Inst. 2001, 93, 266-76.
216. Guzy, R.D.; Schumacker, P.T. Oxygen sensing by mitochondria at complex III: The paradox of increased reactive oxygen species during hypoxia. Exp. Physiol. 2006, 91, 807-819.
217. Chandel, N.S.; McClintock, D.S.; Feliciano, C.E.; Wood, T.M.; Melendez, J.A.; Rodriguez, A.M.; Schumacker, P.T. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α during hypoxia. J. Biol. Chem. 2000, 275, 25130-25138.
218. Brunelle, J.K.; Bell, E.L.; Quesada, N.M.; Vercauteren, K.; Tiranti, V.; Zeviani, M.; Scarpulla, R.C.; Chandel N.S. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. Cell Metab. 2005, 1, 409-414.
219. Mansfield, K.D.; Guzy, R.D.; Pan, Y.; Young, R.M.; Cash, T.P.; Schumacker, P.T.; Simon, M.C. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-α activation. Cell Metab. 2005, 1, 393-399.
220. Sanjuán-Pla, A.; Cervera, A.M.; Apostolova, N.; Garcia-Bou, R.; Victor, V.M.; Murphy, M.P.; McCreath, K.J. A targeted antioxidant reveals the importance of mitochondrial reactive oxygen species in the hypoxic signaling of HIF-1α. FEBS Lett. 2005, 579, 2669-2674.
221. Emerling, B.M.; Platanias, L.C.; Black, E.; Nebreda, A.R.; Davies, R.J.; Chandel, N.S. Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Mol. Cell. Biol. 2005, 25, 4853-4862.
222. Semenza, G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8, S62-S67.
223. Iyer, N.V.; Kotch, L.E.; Agani, F.; Leung, S.W.; Laughner, E.; Wenger, R.H.; Gassmann, M.; Gearhart, J.D.; Lawler, A.M.; Yu, A.Y.; Semenza, G.L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998, 12, 149-162.
224. Gerald, D.; Berra, E.; Frapart, Y.M.; Chan, D.A.; Giaccia, A.J.; Mansuy, D.; Pouyssegur, J.; Yaniv, M.; Mechta-Grigoriou, F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell 2004, 118, 781-794.
225. Papandreou, I.; Cairns, R.A.; Fontana, L.; Lim, A.L.; Denko, N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consmption. Cell Metab. 2006, 3, 187-197.
226. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1 mediated expression of pyruvate. Metabolism 2006, 3, 177-185.
227. Fukuda, R.; Zhang, H.; Kim, J.W.; Shimoda, L.; Dang, C.V.; Semenza, G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 2007, 129, 111-122.
228. Neumann, A.K.; Yang, J.; Biju, M.; Joseph, S.K.; Johnson, R.S., Haase, V.H.; Freedman, B.D.; Turka, L.A. Hypoxia inducible factor 1α regulates T cell receptor signal transduction. Proc. Natl. Acad. Sci. USA 2005, 102, 17071-17076.
229. Huang, Y.; Hickey, R.P., Yeh, J.L., Liu, D.; Dadak, A.; Young, L.H.; Johnson, R.S.; Giordano, F.J. Cardiac myocyte-specific HIF-1α deletion alters vascularization, energy availabilty, calcium flux, and contractility in the normoxic heart. FASEB J. 2004, 18, 1138-1140.
230. Kahn, B.B.; Alquier, T.; Carling, D.; Hardie, D.G. AMP-activated protein kionase: Ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005, 1, 15-25.
231. Reznick, R.M.; Shulman, G.I. The role of AMP-activated protein kinase in mitochondrial biogenesis. J. Physiol. 2006, 574, 33-39.
232. Tzatsos, A.; Tsichlis, P.N. Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J. Biol. Chem. 2007, 282, 18069-18082.
233. Capano, M.; Crompton, M. Bax translocates to mitochondria of heart cells during simulated ischaemia: involvement of AMP-activated and p38 mitogen-activated protein kinases. Biochem. J. 2006, 395, 57-64.
234. Zörning, M.; Hueber, A.O.; Baum, W.; Evan, G. Apoptosis regulators and their role in tumorigenesis. Biochim. Biophys. Acta 2001, 1551, F1-F37.
235. Reed, J.C. Mechanisms of apoptosis avoidance in cancer. Curr. Opinion. Oncol. 1999, 11, 68-75.
236. Burgart, L.J.; Zheng, J.; Shu, Q.; Shibata, D. Somatic mitochondrial mutation in gastric cancer. Am. J. Pathol. 1995, 147, 1105-1111.
237. Didelot, C.; Barberi-Heyob, M.; Bianchi, A.; Becuwe, P.; Mirjolet, J.F.; Dauca, M.; Merlin, J.L. Constitutive NF-kappaB activity influences basal apoptosis and radiosensitivity of head-and-neck carcinoma cell lines. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51, 1354-1360.
238. Takeda, Y.; Togashi, H.; Matsuo, T.; Shinzawa, H.; Takeda, Y.; Takahashi, T. Growth inhibition and apoptosis of gastric cancer cell lines by Anemarrhena asphodeloides Bunge. J. Gastroenterol. 2001, 36, 79-90.
239. Eapen, C.E.; Madesh, M.; Balasubramanian, K.; Pulimood, A.; Mathan, M.; Ramakrishna, B.S. Mucosal mitochondrial function and antioxidant defences in patients with gastric carcinoma. Scand. J. Gastroenterol. 1998, 33, 975-981.
240. Carretero, J.; Obrador, E.; Pellicer, J.A.; Pascual, A.; Estrela, J.M. Mitochondrial glutathione depletion by glutamine in growing tumor cells. Free Rad. Biol. Med. 2000, 29, 913-923.
241. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57-70.
242. Wu, M.; Neilson, A.; Swift, A.L.; Moran, R.; Tamagnine, J.; Parslow, D.; Armistead, S.; Lemire, K.; Orrell, J.; Teich, J.; Chomicz, S.; Ferrick, D.A. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am. J. Physiol. 2007, 292, C125-C136.
243. Dang, C.V.; Semenza, G.L. Oncogenic alterations of metabolism. Trends. Biochem. 1999, 24, 68-72.
244. Semenza, G.L.; Artemov, D.; Bedi, A.; Bhujwalla, Z.; Chiles, K.; Feldser, D.; Laughner, E.; Ravi, R.; Simons, J.; Taghavi, P.; Zhong, H. 'The metobolism of tumors': 70 years later. Novartis Found. Symp. 2001, 240, 251-260.
245. Fantin, V.R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006, 9, 426-434.
246. Matoba, S.; Kang, J.G.; Patino, W.D.; Wragg, A.; Boehm, M.; Gavrilova, O.; Hurley, P.J.; Bunz, F.; Hwang, P.M. P53 regulates mitochondrial respiration. Science 2006, 312, 1650-1653.
247. Shim, H.; Dolde, C.; Lewis, B.C.; Wu, C.S.; Dang, G.; Jungmann, R.A.; Dalla-Favera, R.; Dang, C.V. C-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc. Natl. Acad. Sci. USA 1997, 94, 6658-6663.
248. Dang, C.V. The interplay between MYC and HIF in the Warburg effect. Ernst Schering Found. Symp. Proc. 2007, 4, 35-53.
249. Lu, H.; Dalgard, C.L.; Mohyeldin, A.; McFate, T.; Tait, A.S.; Verma, A. Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1a. J. Biol. Chem. 2005, 280, 41928-41939.
250. McFate, T.; Mohyeldin, A.; Lu, H.; Thakar, J.; Henriques, J.; Halim, N.D.; Wu, H.; Schell, M J.; Tsang, T.M.; Teahan, O.; Zhou, S.; Califano, J.A.; Jeoung, N.H.; Harris, R.A.; Verma, A. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J. Biol.Chem. 2008, 283, 22700-22708.
251. Dalgard, C.L.; Lu, H.; Mohyeldin, A.; Verma, A. Endogenous 2-oxoacids differentially regulate expression of oxygen sensors. Biochem. J. 2004, 380, 419-424.
252. Baysal, B.E.; Ferrell, R.E.; Willett-Brozick, J.E.; Lawrence, E.C.; Myssiorek, D.; Bosch, A.; van der Mey, A; Taschner, P.E.; Rubinstein, W.S.; Myers, E.N.; Richard, C.W., 3rd; Cornelisse, C.J.; Devilee, P.; Devlin, B., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287, 848-851.
253. Briere, J.; Favier, J., Benit, P.; El Ghouzzi, V.; Lorenzato, A.; Babier, D.; Di Renzo, M.F.; Gimenez-Roqueplo, A.P.; Rustin, P. Mitochondrial succinate is instrumental for HIF1a nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Human Mol. Gen. 2005, 14, 3263-3268.
254. Selak, M.A.; Armour, S.M.; MacKenzie, E.D.; Boulahbel, H.; Watson, D.G.; Mansfield, K.D.; Pan, Y.; Simon, M.C.; Thompson, C.B.; Gottlieb, E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005, 7, 77-85.
255. Gottlieb, E.; Tomlinson, I.P. Mitochondrial tumor suppressors: a genetic and biochemical update. Nat. Rev. Cancer 2005, 5, 857-866.
256. Levine, A.J.; Feng, Z.; Mak, T.W.; You, H.; Jin, S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 2006, 20, 267-275.
257. Kondoh, H.; Lleonart, M.E.; Gil, J.; Wang, J.; Degan, P.; Peters, G.; Martinez, D.; Carnero, A.; Beach, D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65, 177-185.
258. Jones, R.G.; Plas, D.R.; Kubek, S.; Buzzai, M.; Mu, J.; Xu, Y.; Birnbaum, M.J.; Thompson, C.B. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 2005, 18, 283-293.
259. Buzzai, M.; Jones, R.G.; Amaravadi, R.K.; Lum, J.J.; DeBerardinis, R.J.; Zhao, F.; Viollet, B.; Thompson, C. Systemic treatment with the antidiabetic drug metformin selectively impairs p53- deficient tumor cell growth. Cancer Res. 2007, 67, 6745-6752.
260. Ainscow, E.K.; Zhao, C.; Rutter, G.A. Acute overexpression of lactate dehydrogenase-A perturbs b-cell mitochondrial metabolism and insulin secretion. Diabetes 2000, 49, 1149-1155.
261. Golshani-Hebroni, S.G.; Bessman, S.P. Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J. Bioenerg. Biomembr. 1997, 29, 331-338.
262. Pelicano, H.; Xu, R.; Du, M.; Feng, L.; Sasaki, R.; Carew, J.S.; Hu, Y.; Ramdas, L.; Hu, L.; Keating, M.J.; Zhang, W.; Plunkett, W.; Huang, P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J. Cell. Biol. 2006, 175, 913-923.
263. Tomiyama, A.; Serizawa, S.; Tachibana, K.; Sakurada, K.; Samejima, H.; Kuchino, Y.; Kitanaka, C. Critical role for mitochondrial oxidative phosphorylation in the activation of tumor suppressors Bax and Bak. J. Natl. Cancer Inst. 2006, 98, 1462-1473.
264. Chandra, D.; Liu, J.W.; Tang, D.G. Early mitochondrial activation and cytochrome c upregulation during apoptosis. J. Biol. Chem. 2004, 277, 50842-50854.
265. Kwong, J.Q.; Henning, M.S.; Starkov, A.A.; Manfredi, G. The mitochondrial respiratory chain is a modulator of apoptosis. J. Cell Biol. 2007, 179, 1163-1177.
266. Miyashita, T.; Reed, J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80, 293-299.
267. Miyashita, T.; Harigai, M.; Hanada, M.; Reed, J.C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994, 54, 3131-3135.
268. Oda, E.; Ohki, R.; Murasawa, H.; Nemoto, J.; Shibue, T.; Yamashita, T.; Tokino, T.; Taniguchi, T.; Tanaka, N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53- induced apoptosis. Science 2000, 288, 1053-1058.
269. Oda, K.; Arakawa, H.; Tanaka, T.; Matsuda, K.; Tanikawa, C.; Mori, T.; Nishimori, H.; Tamai, K.; Tokino, T.; Nakamura, Y.; Taya, Y. P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102, 849-862.
270. Nakano, K.; Vousden, K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7, 683-694.
271. Hoffman, W.H.; Biade, S.; Zilfou, J.T.; Chen, J.; Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002, 277, 3247-3257.
272. Zhao, Y.; Chaiswing, L.; Velez, J.M.; Batinic-Haberle, I.; Colburn, N.H.; Oberley, T.D.; St. Clair, D.K. p53 translocation to mitochondria precedes its nuclear translocation and targets mitochondrial oxidative defense protein-manganese superoxide dismutase. Cancer Res. 2005, 65, 3745-375.
273. Pietsch, E.C.; Perchiniak, E.; Canutescu, A.A.; Wang, G.; Dunbrack, R.L.; Murphy, M.E. Oligomerization of BAK by p53 utilizes conserved residues of the p53 DNA binding domain. J. Biol. Chem. 2008, 283, 21294-21304.
274. Li, P.F.; Dietz, R.; von Harsdorf, R. P53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent aoptosis blocked by Bcl-2. EMBO J. 1999, 18, 6027-6036.
275. Marchenko, N.D.; Zaika, A.I.; Moll, U.M. Death signal induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J. Biol. Chem. 2000, 275, 16202-16212.
276. Erster, S.; Mihara, M.; Kim, R.H.; Petrenko, O.; Moll, U.M. In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol. 2004, 15, 6728-6741.
277. Schuler, M.; Bossy-Wetzel, E.; Goldstein, J.C.; Fitzgerald, P.; Green, D.R. P53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J. Biol. Chem. 2000, 275, 7337-7342.
278. Ding, H.F.; Lin, Y.L.; McGill, G.; Juo, P.; Zhu, H.; Blenis, J.; Yuan, J.; Fisher, D.E. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J. Biol. Chem. 2000, 275, 38905-38911.
279. Simonnet, H.; Demont, J.; Pfeiffer, K.; Guenaneche, L.; Bouvier, R.; Brandt, U.; Schagger, H.; Godinot, C. Mitochondrial complex I is deficient in renal oncocytomas. Carcinogenesis 2003, 24, 1461-1466.
280. Bonora, E.; Porcelli, A.M.; Gasparre, G.; Biondi, A.; Ghelli, A.; Carelli, V.; Baracca, A.; Tallini, G.; Martinuzzi, A.; Lenaz, G.; Rugolo, M.; Romeo, G. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res. 2006, 66, 6087-6096.
281. Petros, J.A.; Baumann, A.K.; Ruiz-Pesini, E.; Amin, M.B.; Sun, C.Q.; Hall, J.; Lim, S.; Issa, M.M.; Flanders, W.D.; Hosseini, S.H.; Marshall, F.F.; Wallace, D.C. mtDNA mutations increase tumorigenicity in prostate cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 719-724.
282. Boitier, F.; Merad-Boudina, M.; Guguen-Guillouzo, C.; Defer, N.; Ceballos-Picot, I.; Leroux, J.P.; Marsac C. Impairment of the mitochondrial respiratory chain activity in diethylnitrosamineinduced rat hepatomas: possible involvement of oxygen free radicals. Cancer Res. 1995, 55, 3028-3035.
283. Ray, S.; Ray, M. Does excessive adenosine 5'-triphosphate formation in cells lead to malignancy? A hypothesis on cancer. Medical Hypotheses 1997, 48, 473-476.
284. Capuano, F.; Varone, D.; D'Eri, N.; Russo, E.; Tommasi, S.; Montemurro, S.; Prete, F.; Papa, S. Oxidative phosphorylation and F(O)F(1) ATP synthase activity of human hepatocellular carcinoma. Biochem. Mol. Biol. Int. 1996, 38, 1013-1022.
285. Green, D.W.; Grover, G.J. The IF(1) inhibitor protein of the mitochondrial F(1)F(0)-ATPase. Biochim. Biophys. Acta 2000, 1458, 343-355.
286. Bravo, C.; Minauro-Sanmiguel, F.; Morales-Rios, E.; Rodriguez-Zavala, J.S.; Garcia, J.J. Overexpression of the inhibitor protein IF(1) in AS-30D hepatoma produces a higher association with mitochondrial F(1)F(0) ATP synthase compared to normal rat liver: functional and crosslinking studies. J. Bioenerg. Biomembr. 2004, 36, 257-264.
287. Cuezva, J.M.; Krajewska, M.; de Heredia, M.L.; Krajewski, S.; Santamaria, G.; Kim, H.; Zapata, J.M.; Maruzawa, H.; Chamorro, M.; Reed, J.C. The bioenergetic signature of cancer: a marker of tumor progression. Cancer Res. 2002, 62, 6674-6681.
288. Cuezva, J.M.; Chen, G.; Alonso, A.M.; Isidoro, A.; Misek, D.E; Hanash, S.M.; Beer, D.G. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004, 25, 1157-1163.
289. Isodoro, A.; Casado, E.; Redondo, A.; Acebo, P.; Espinosa, E.; Alonso, A.M.; Cejas, P.; Hardisson, D.; Fresno Vara., J.A.; Belda-Iniesta, C.; Gonzales-Baron, M.; Cuezva, J.M. Breast carcinomas fulfill the Warburg hypothesi and provide metabolic markers of cancer prognosis. Carcinogenesis 2005, 26, 2095-2104.
290. Simonnet, H.; Alazard, N.; Pfeiffer, K.; Gallou, C.; Beroud, C.; Demont, J.; Bouvie, R.; Schagger, H.; Godinot, C. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002, 23, 759-768.
291. Kuhnt, T.; Pelz, T.; Qu, X.; Hansgen, G.; Dunst, J.; Gellerich, F.N. Mitochondrial OXPHOS Functions in R1H Rhabdomyosarcoma and Skeletal Muscles of the Rat. Neurochem Res. 2007, 32, 973-980.
292. Spitz, D.R.; Sim, J.E.; Ridnour, L.A.; Galoforo, S.S.; Lee, Y.J. Glucose deprivation-induced oxidative stress in human tumor cells. A fundamental defect in metabolism? Ann. NY Acad. Sci. 2000, 899, 349-362.
293. Ahmad, I.M.; Aykin-Burns, N.; Sim, J.E.; Walsh, S.A; Higashikubo, R.; Buettner, G.R.; Venkataraman, S.; Mackey, M.A.; Flanagan, S.; Oberley, L.W.; Spitz, D.R. Mitochondrial O2*- and H2O2 mediate glucose deprivation-induced stress in human cancer cells. J. Biol. Chem. 2005, 280, 4525-4563.
294. Pedram, A.; Razandi, M.; Wallace, D.C.; Levin, A.R. Functional estrogen receptors in the mitochondria of breast cancer cells. Mol. Biol. Cell 2006, 17, 2125-2137
295. Hussain, S.P.; Hofseth, L.J.; Harris, C.C. Radical causes of cancer. Nat. Rev. Cancer 2003, 3, 276-285.
296. Hervouet, E.; Simonnet, H.; Godinot, C. Mitochondria and reactive oxygen species in renal cancer. Biochimie 2007, 89, 1080-1088.
297. Schumacker, P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006, 10, 175-176.
298. Lu, F. Reactive oxygen species in cancer, too much or too little? Med. Hypoth. 2007, 69, 1293-1298.
299. Korshunov, S.S.; Skulachev, V.P.; Starkov, A.A. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria. FEBS Lett. 1997, 416, 15-18.
300. Santamaría, G.; Martínez-Diez, M.; Fabregat, I.; Cuezva, J.M. Efficient execution of cell death in non-glycolytic cells requires the generation of ROS controlled by the activity of mitochondrial H+-ATP synthase. Carcinogenesis 2006, 27, 925-935.
301. Horimoto, M.; Resnick, M.B.; Konkin, T.A.; Routhier, J.; Wands, J.R.; Baffy, G. Expression of uncoupling protein-2 in human colon cancer. Clin. Cancer Res. 2004, 10, 6203-6207.
302. Harper, M.E.; Antoniou, A.; Villalobos-Menuey, E.; Russo, A.; Trauger, R.; Vendemelio, M.; George, A.; Bartholomew, R.; Carlo, D.; Shaikh, A.; Kupperman, J.; Newell, E.W.; Bespalov, I.A.; Wallace, S.S.; Liu, Y.; Rogers, J.R.; Gibbs, G.L.; Leahy, J.L.; Camley, R.E.; Melamede, R.; Newell, M.K. Characterization of a novel metabolic strategy used by drug-resistant tumor cells. FASEB J. 2002, 16, 1550-1557.
303. Collins, P.; Jones, C.; Choudhury, S.; Damelin, L.; Hodgson, H. Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis. Liver Int. 2005, 25, 880-887.
304. Derdak, Z.; Mark, N.M.; Beldi, G.; Robson, S.C.; Wands, J.R.; Baffy, G. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res. 2008, 68, 2813-2819.
305. Chan S.L.;Yu, V.C. Proteins of the Bcl-2 family in apoptosis signalling: from mechanistic insights to therapeutic opportunities. Clin. Exp. Pharmacol. Physiol. 2004, 31, 119-128.
306. Kirkin, V.; Joos, S.; Zörning, M. The role of Bcl-2 family members in tumorigenesis. Biochim. Biophys. Acta 2004, 1644, 229-249.
307. Sekimura, A.; Konishi, A.; Mizuno, K.; Kobiyashi, Y.; Sasaki, H.; Yano, M.; Fukai, I.; Fujii, Y. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol. Rep. 2004, 11, 797-802.
308. Mizutani, Y.; Nakanishi, H.; Yamamoto, K.; Li, Y.N.; Matsubara, H.; Mikami, K.; Okihara, K.; Kawauchi, A.; Bonavida, B.; Miki, T. Downregulation of Smac/DIABLO expression in renal cell carcinoma and its prognostic significance. J. Clin. Oncol. 2004, 23, 448-454.
309. Zörning, M.; Hueber, A.O.; Baum, W.; Evan, G. Apoptosis regulators and their role in tumorigenesis. Biochim. Biophys. Acta 2001, 1551, F1-F37.
310. Dohi, T.; Beltrami, E.; Wall, N.R.; Plescia, J.; Altieri, D.C. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest. 2004, 114, 1117-1127.
311. Hajra, K.M.; Liu, J.R. Apoptosome dysfunction in human cancer. Apoptosis 2004, 9, 691-704.
312. Nakashima, R.A.; Paggi, M.G.; Scott, L.J.; Pedersen, P.L. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the high glycolytic AS-30D rat hepatoma cell line. Cancer Res. 1988, 48, 913-919.
313. Mathupala, S.P.; Rempel, A.; Pedersen, P.L. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J. Biol. Chem. 1995, 270, 16918-16925.
314. Mathupala, S.P.; Ko, Y.H.; Pedersen, P.L. Hexokinase II: cancer's double edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006, 25, 4777-4786.
315. Gwak, G.Y.; Yoon, J.H.; Kim, K.M.; Lee, H.S.; Chung, J.W.; Gores, G.J. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J. Hepatol. 2005, 42, 358-364.
316. Nicholson, K.M.; Anderson, N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Sign. 2002, 14, 381-395.
317. Majewski, N.; Nogueira, V.; Robey, R.B.; Hay N. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol. Cell. Biol. 2004, 24, 730-740.
318. Pastorino, J.; Hoek, J.B.; Shulga, N. Activation of gkycogen synthase kinase 3b disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res. 2005, 65, 10545-10554.
319. Mathupala, S.P.; Ko, Y.H.; Pedersen, P.L. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin. Cancer Biol. 2009, 19, 17-24.
320. Chiara, F.; Castellaro, D.; Marin, O.; Petronilli, V.; Brusilow, W.S.; Juhaszova, M.; Sollott, S.J.; Forte, M.; Bernardi, P.; Rasola, A. Hexokinase II detachment from mitochondria triggers apoptosis through the permeability transition pore independent of voltage-dependent anion channels. PLoS ONE 2008, 3, e1852, 1-11.
321. Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria in cancer cells: what is so special about them? Trends Cell Biol. 2008, 18, 165-173.
322. Török, N.J.; Higuchi, H.; Bronk, S.; Goers, G.J. Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9. Cancer Res. 2001, 62, 1648-1653.
323. Lester, R.D.; Jo, M.; Campana, W.M.; Gonias, S.L. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. J. Biol. Chem. 2005, 280, 39273-39277.
324. Galiègue, S.; Casellas, P.; Kramar, A.; Tinel, N.; Simony-Lafontaine, J. Immunohistochemical assessment of the peripheral benzodiazepine receptor in breat cancer and its relationship with survival. Clin. Cancer Res. 2004, 10, 2058-2064.
325. Carayon, P.; Portier, M.; Dussossoy, D.; Bord, A.; Petiprêtre, G.; Canat, X.; Le Fur, G.; Casellas, P. Involvement of peripheral benzodiazepine receptors in the protection of hematopoietic cells against oxygen radical damage. Blood 1996, 87, 3170-3178.
326. Denicourt, C.; Dowdy, S. Targeting apoptotic pathways in cancer cells. Science 2004, 305, 1411-1413.
327. Anderson, K.M.; Harris, J.E. Is induction of type 2 programmed death in cancer cells from solid tumors directly related to mitochondrial mass? Med. Hypoth. 2001, 57, 87-90.
328. Grad, J.M.; Cepero, E.; Boise, L.H. Mitochondria as targets for established and novel anti-cancer agents. Drug Resist. Updat. 2001, 4, 85-91.
329. Zhang, L.; Yu, J.; Park, B.H.; Kinzler, K.W.; Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 2000, 290, 989-992.
330. Zimmermann, K.C.; Waterhouse, N.J.; Goldstein, J.C.; Schuler, M.; Green D.R. Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia (NY) 2000, 2, 505-513.
331. Correa, P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 1992, 52, 6735-6740.
332. Correa, P. The biological model of gastric carcinogenesis. IARC Sci. Pub. 2004, 301-310.
333. Gruno, M.; Peet, N.; Seppet, E.; Kadaja, L.; Paju, K.; Eimre, M.; Orlova, E.; Peetsalu, M.; Tein, A.; Soplepmann, J.; Schlattner, U.; Peetsalu, A.; Seppet, E.K. Oxidative phosphorylation and its coupling to mitochondrial creatine and adenylate kinases in human gastric mucosa. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291, R936-946.
334. Bayerdorffer, E.; Lehn, N.; Hatz, R.; Mannes, G.A.; Oertel, H.; Sauerbruch, T.; Stolte, M. Difference in expression of Helicobacter pylori gastritis in antrum and body. Gastroenterology 1992, 102, 1575-1582.
335. Fu, S.; Ramanujam, K.S.; Wong, A.; Fantry, G.T.; Drachenberg, C.B.; James, S.P.; Meltzer, S.J.; Wilson, K.T. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999, 116, 1319-1329.
336. Ozawa, K.; Kato, S.; Sekine, H.; Koike, T.; Minoura, T.; Iinuma, K.; Nagura, H. Gastric epithelial cell turnover and mucosal protection in Japanese children with Helicobacter pylori infection. J. Gastroenterol. 2005, 40, 236-246.
337. Maeda, S.; Yoshida, H.; Mitsuno, Y.; Hirata, Y.; Ogura, K.; Shiratori, Y.; Omata, M. Analysis of apoptotic and antiapoptotic signalling pathways induced by Helicobacter pylori. Gut 2002, 50, 771-778.
338. Yanai, A.; Hirata, Y.; Mitsuno, Y.; Maeda, S.; Shibata, W.; Akanuma, M.; Yoshida, H.; Kawabe, T.; Omata, M. Helicobacter pylori induces antiapoptosis through buclear factor-kappaB activation. J. Infect. Dis. 2003, 188, 1741-1751.
339. McCarthy, C.J.; Crofford, L.J.; Greenson, J.; Scheiman, J.M. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am. J. Gastroenterol. 1999, 94, 1218-1223.
340. Sung, J.J.; Leung, W.K.; Go, M.Y.; To, K.F.; Cheng, A.S.; Ng, E.K.; Chan, F.K. Cyclooxygenase-2 expression in Helicobacter pylori-associated premalignant and malignant gastric lesions. Am. J. Pathol. 2000, 157, 729-735.
341. Gupta, R.A.; Polk, D.B.; Krishna, U.; Israel, D.A.; Yan, F.; DuBois, R.N.; Peek, R.M., Jr. Activation of peroxisome proliferator-activated receptor gamma suppresses nuclear factor kappa B-mediated apoptosis induced by Helicobacter pylori in gastric epithelial cells. J. Biol. Chem. 2001, 276, 31059-31066.
342. Peek, R.M., Jr.; Blaser, M.J. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat. Rev. Cancer 2002, 2, 28-37.
343. Lehman, J.J.; Barger, P.M.; Kovacs, A.; Saffitz, J.E.; Medeiros, D.M.; Kelly, D.P. Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J. Clin. Invest. 2000, 106, 847-856.
344. Czubryt, M.P.; McAnally, J.; Fishman, G.I.; Olson, E.N. Regulation of peroxisome proliferatoractivated receptor gamma coactivator 1 alpha (PGC-1 alpha) and mitochondrial function by MEF2 and HDAC5. Proc. Natl. Acad. Sci. USA 2003, 100, 1711-1716.
345. Valle, J.; Kekki, M.; Sipponen, P.; Ihamaki, T.; Siurala, M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand. J. Gastroenterol. 1996, 31, 546-550.
346. Sipponen, P.; Kekki, M.; Haapakoski, J.; Ihamaki, T.; Siurala, M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int. J. Cancer. 1985, 35, 173-177.
347. Yin, G.Y.; Zhang, W.N.; He, X.F.; Chen, Y.; Shen, X.J. Study on the classification of chronic gastritis at molecular biological level. World J. Gastroenterol. 2003, 9, 836-842.
348. Gruno, M.; Peet, N.; Tein, A.; Salupere, R.; Sirotkina, M.; Valle, J.; Peetsalu, A.; Seppet, E.K. Atrophic gastritis: deficient complex I of the respiratory chain in the mitochondria of corpus mucosal cells. J. Gastroenterol. 2008, 43, 780-788.
349. Zhong, H.; De Marzo, A.M.; Laughner, E.; Lim, M.; Hilton, D.A.; Zagzag, D.; Buechler, P.; Isaacs, W.B.; Semenza, G.L.; Simons, J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59, 5830-5835.
350. Griffits, E.A.; Pritchard, S.A.; Valentine, H.R.; Whitchelo, N.; Bishop, P.W.; Ebert, M.P.; Proce, P.M.; Welch, I.M.; West, C.M. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. Br. J. Cancer 2007, 96, 95-103.
351. Griffits, E.A.; Pritchard, S.A.; McGrath, S.M.; Valentine, H.R.; Price, P.M.; Welch, I.M.; West, C.M. Hypoxia-associated markers in gastric carcinogenesis and HIF-2appha in gastric and gastro-oesophageal cancer prognosis. Br. J. Cancer 2008, 98, 965-973.
352. Stoeltzing, O.; McCarty, M.F.; Wey, J.S.; Fan, F.; Liu, W.; Belcheva, A.; Bucana, C.D.; Semenza, C.L.; Ellis, L.M. Role of hypoxia-inducible factor 1a in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Nat.Cancer Inst. 2004, 96, 946-956.
353. Treins, C.; Gioergetti-Peraldi, S.; Murdaca, J.; Semenza, G.L.; Van Obberghen, E. Insulin stimulates hypoxia inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J. Biol. Chem. 2002, 277, 27975-27981.
354. Mayerhofer, M.; Valent, P.; Sperr, W.R.; Griffin, J.D.; Sillaber, C. BCR/ABL induces expression of vascular endothelial growth factor and its transcription activator, hypoxia inducible factor-1a, through a pathway involiving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood 2002, 100, 3767-3775.
355. Lang, S.A.; Gaumann, A.; Koehl, G.E.; Seidel, U.; Bataille, F.; Klein, D.; Ellis, L.M.; Bolder, U.; Hofstaedter, F.; Schlitt, H.J.; Geissler, E.K.; Stoeltzing, O. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer 2007, 120, 1803-1810.
356. Kolev, Y.; Uetake, H.; Takagi, Y.; Sugihara, K. Lactate dehydrogenase-5 (LDH-5) expression in human gastric cancer: association with hypoxia-inducible factor (HIF-1alpha) pathway, angiogenic factors production and poor prognosis. Ann. Surg. Oncol. 2008, 15, 2336-2344.
357. Larsson, N.G.; Luft R. Revolution in mitochondrial medicine. FEBS Lett. 1999, 455, 199-202.
358. Zou, M.H.; Kirkpatrick, S.S.; Davie, B.J.; Nelson, J.S.; Wiles, W.G., IV; Schlattner, U.; Neumann, D.; Brownlee, M.; Freeman, M.B.; Gioldman, M.H. Activation of the AMP-activated protein kinase by the antidiabetic drug metformin in vivo. J. Biol. Chem. 2004, 279, 43940-43951.
359. Brunmair, B.; Staniek, K.; Gras, F.; Scharf, N.; Althaym, A.; Clara, R.; Roden, M.; Gnaiger, E.; Nohl, H.; Waldhäusl, W.; Fürnsinn, C. Thiazolidinediones, like metformin, inhibit respiratory complex I. Diabetes 2004, 53, 1052-1059.
360. Wang, W; Lopaschuk, G.D. Metabolic therapy for the treatment of ischemic heart disease: reality and expectations. Exp. Rev. Cardiovasc. Ther. 2007, 5, 1123-1134.
361. Kroemer, G. Mitochondria in cancer. Oncogene 2006, 25, 4630-4632.